Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

about

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

P2860

Q53578474-FDEF7146-DD16-46B8-9515-E0B8F9FEC6E7

P2860

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

Item

http://www.wikidata.org/entity/Q36771017

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@ast

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@en

type

Item

label

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@ast

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@en

prefLabel

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@ast

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

@en

P1476

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors

@en

P2093

Adam Schiro

http://www.w3.org/2001/XMLSchema#string

Barbara Zarebczan

http://www.w3.org/2001/XMLSchema#string

Herbert Chen

http://www.w3.org/2001/XMLSchema#string

Holly C Gillis

http://www.w3.org/2001/XMLSchema#string

Scott N Pinchot

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group

Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract.

The surgical spectrum of pulmonary neuroendocrine neoplasms.

Current management of gastrointestinal carcinoid tumors.

Surgical treatment of advanced-stage carcinoid tumors: lessons learned.

Imaging of neuroendocrine tumors.

Diagnosis and treatment of Zollinger-Ellison syndrome.

Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).

Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids.

Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.

P2888

s10434-012-2617-7

P304

640-645

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-012-2617-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Narek Shaverdian

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023721722

http://www.w3.org/2001/XMLSchema#string

P698

22941169

http://www.w3.org/2001/XMLSchema#string

P932

4822699

http://www.w3.org/2001/XMLSchema#string

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

about

P2860

P2860

Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932